Reviva Pharmaceuticals Holdings (RVPH) Non Operating Income (2021 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Non Operating Income of $79311.0 for Q1 2026, down 59.17% sequentially from $194244.0 in Q4 2025, and down 28.25% YoY from $110540.0 in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Non Operating Income (2021 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Non Operating Income for 6 years, with the latest figure at $79311.0 in Q1 2026.
- Quarterly Non Operating Income fell 28.25% year-over-year to $79311.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $322789.0 (down 37.23% YoY) and the FY2025 annual result came in at $354018.0, down 60.65% from the prior year.
- Non Operating Income fell to $79311.0 in Q1 2026 per RVPH's latest filing, from $194244.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $495894.0 in Q1 2024 and troughed at -$365875.0 in Q2 2023.
- A 5-year average of $92986.5 and a median of $96736.0 in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income plunged 297.02% in 2023, then jumped 550.47% in 2025.
- Over 5 years, Non Operating Income stood at -$335899.0 in 2022, then soared by 177.26% to $259500.0 in 2023, then tumbled by 88.49% to $29862.0 in 2024, then surged by 550.47% to $194244.0 in 2025, then tumbled by 59.17% to $79311.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $79311.0, $194244.0, and $21908.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | 172,344.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 172,344.00 |
| Mar 31, 2026 | 79,311.00 |
| Dec 31, 2025 | 194,244.00 |
| Sep 30, 2025 | 21,908.00 |
| Jun 30, 2025 | 27,326.00 |
| Mar 31, 2025 | 110,540.00 |
| Dec 31, 2024 | 29,862.00 |
| Sep 30, 2024 | 96,736.00 |
| Jun 30, 2024 | 277,109.00 |
| Mar 31, 2024 | 495,894.00 |
| Dec 31, 2023 | 259,500.00 |
| Sep 30, 2023 | 230,135.00 |
| Jun 30, 2023 | -365,875.00 |
| Mar 31, 2023 | 135,988.00 |
| Dec 31, 2022 | -335,899.00 |
| Sep 30, 2022 | 49,509.00 |
| Jun 30, 2022 | 185,705.00 |
| Mar 31, 2022 | 88,778.00 |
| Dec 13, 2021 | 279,690.00 |
| Sep 30, 2021 | 199,726.00 |